| Abemaciclib and Anastrozole |
3 |
12 |
|
| Abemaciclib and Camizestrant |
1 |
1 |
|
| Abemaciclib and Exemestane |
3 |
6 |
|
| Abemaciclib and Fulvestrant |
3 |
9 |
|
| Abemaciclib and Letrozole |
3 |
12 |
|
| Abemaciclib and Tamoxifen |
3 |
6 |
|
| Abiraterone acetate, Niraparib, and Prednisolone |
4 |
8 |
|
| Abiraterone acetate, Niraparib, and Prednisone |
4 |
10 |
|
| Abiraterone acetate, Olaparib, and Prednisolone |
4 |
4 |
|
| Abiraterone acetate, Olaparib, and Prednisone |
4 |
4 |
|
| Adagrasib and Cetuximab |
1 |
1 |
|
| Alpelisib and Fulvestrant |
3 |
6 |
|
| Amivantamab, Carboplatin, and Pemetrexed |
3 |
6 |
|
| Amivantamab and Lazertinib |
2 |
10 |
|
| Anastrozole, Goserelin, and Ribociclib |
3 |
6 |
|
| Anastrozole and Ribociclib |
3 |
3 |
|
| Anastrozole and Trastuzumab |
6 |
6 |
|
| Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel |
3 |
3 |
|
| Atezolizumab, Carboplatin, and Nab-paclitaxel |
3 |
3 |
|
| Atezolizumab, Carboplatin, and Paclitaxel |
1 |
1 |
|
| Atezolizumab, Cobimetinib, and Vemurafenib |
2 |
2 |
|
| Atezolizumab and Nab-paclitaxel |
1 |
1 |
|
| Avutometinib and Defactinib |
2 |
2 |
|
| Azacitidine and Ivosidenib |
5 |
10 |
|
| Bevacizumab, Carboplatin, Paclitaxel, and Pembrolizumab |
2 |
3 |
|
| Bevacizumab, Cisplatin, Paclitaxel, and Pembrolizumab |
2 |
2 |
|
| Bevacizumab and Erlotinib |
2 |
2 |
|
| Bevacizumab and Olaparib |
15 |
30 |
|
| Bevacizumab, Paclitaxel, and Pembrolizumab |
3 |
6 |
|
| Binimetinib and Encorafenib |
3 |
12 |
|
| Brentuximab vedotin, Cyclophosphamide, Dacarbazine, Dexamethasone, Doxorubicin, and Etoposide |
1 |
1 |
|
| Brentuximab vedotin, Cyclophosphamide, Doxorubicin, and Prednisone |
1 |
1 |
|
| Brentuximab vedotin, Dacarbazine, Doxorubicin, and Vinblastine |
1 |
1 |
|
| Camizestrant and Palbociclib |
1 |
1 |
|
| Camizestrant and Ribociclib |
1 |
1 |
|
| Capecitabine, Cisplatin, and Tislelizumab |
3 |
3 |
|
| Capecitabine, Cisplatin, and Trastuzumab |
2 |
2 |
|
| Capecitabine and Lapatinib |
2 |
3 |
|
| Capecitabine and Margetuximab |
1 |
1 |
|
| Capecitabine and Neratinib |
1 |
1 |
|
| Capecitabine, Nivolumab, and Oxaliplatin |
3 |
3 |
|
| Capecitabine, Oxaliplatin, and Pembrolizumab |
1 |
1 |
|
| Capecitabine, Oxaliplatin, Pembrolizumab, and Trastuzumab |
1 |
1 |
|
| Capecitabine, Oxaliplatin, and Tislelizumab |
6 |
6 |
|
| Capecitabine, Oxaliplatin, and Zolbetuximab |
1 |
2 |
|
| Capecitabine, Trastuzumab, and Tucatinib |
1 |
2 |
|
| Capivasertib and Fulvestrant |
22 |
29 |
|
| Carboplatin, Cemiplimab, and Pemetrexed |
2 |
2 |
|
| Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, and Pembrolizumab |
1 |
2 |
|
| Carboplatin, Docetaxel, Pertuzumab, and Trastuzumab |
1 |
4 |
|
| Carboplatin, Docetaxel, and Trastuzumab |
2 |
2 |
|
| Carboplatin, Dostarlimab, and Paclitaxel |
2 |
2 |
|
| Carboplatin, Durvalumab, Gemcitabine, and Tremelimumab |
1 |
2 |
|
| Carboplatin, Durvalumab, Nab-paclitaxel, and Tremelimumab |
1 |
2 |
|
| Carboplatin, Durvalumab, Olaparib, and Paclitaxel |
1 |
1 |
|
| Carboplatin, Durvalumab, and Paclitaxel |
2 |
4 |
|
| Carboplatin, Durvalumab, and Pemetrexed |
1 |
2 |
|
| Carboplatin, Durvalumab, Pemetrexed, and Tremelimumab |
1 |
2 |
|
| Carboplatin, Durvalumab, and Tremelimumab |
1 |
2 |
|
| Carboplatin, Fluorouracil, and Pembrolizumab |
2 |
2 |
|
| Carboplatin, Fluorouracil, Pembrolizumab, and Trastuzumab |
1 |
1 |
|
| Carboplatin, Gemcitabine, and Pembrolizumab |
2 |
3 |
|
| Carboplatin, Ipilimumab, Nivolumab, and Paclitaxel |
1 |
4 |
|
| Carboplatin, Ipilimumab, Nivolumab, and Pemetrexed |
1 |
4 |
|
| Carboplatin, Nivolumab, and Paclitaxel |
2 |
3 |
|
| Carboplatin, Nivolumab, and Pemetrexed |
1 |
2 |
|
| Carboplatin and Osimertinib |
2 |
2 |
|
| Carboplatin, Osimertinib, and Pemetrexed |
2 |
2 |
|
| Carboplatin, Paclitaxel, and Pembrolizumab |
3 |
4 |
|
| Carboplatin, Pembrolizumab, and Pemetrexed |
1 |
2 |
|
| Carboplatin, Pemetrexed, and Tislelizumab |
1 |
1 |
|
| Cetuximab and Encorafenib |
1 |
4 |
|
| Cetuximab, Encorafenib, Fluorouracil, and Irinotecan |
1 |
1 |
|
| Cetuximab, Encorafenib, Fluorouracil, and Oxaliplatin |
1 |
3 |
|
| Cetuximab, Fluorouracil, and Irinotecan |
1 |
1 |
|
| Cetuximab, Fluorouracil, and Oxaliplatin |
1 |
1 |
|
| Cetuximab and Irinotecan |
2 |
2 |
|
| Cisplatin, Docetaxel, and Nivolumab |
1 |
1 |
|
| Cisplatin, Durvalumab, and Gemcitabine |
1 |
2 |
|
| Cisplatin, Durvalumab, Gemcitabine, and Tremelimumab |
1 |
2 |
|
| Cisplatin, Durvalumab, and Pemetrexed |
1 |
2 |
|
| Cisplatin, Durvalumab, Pemetrexed, and Tremelimumab |
1 |
2 |
|
| Cisplatin, Fluorouracil, and Nivolumab |
1 |
1 |
|
| Cisplatin, Fluorouracil, and Pembrolizumab |
4 |
4 |
|
| Cisplatin, Fluorouracil, Pembrolizumab, and Trastuzumab |
1 |
2 |
|
| Cisplatin, Fluorouracil, and Tislelizumab |
6 |
6 |
|
| Cisplatin, Fluorouracil, and Trastuzumab |
2 |
2 |
|
| Cisplatin, Gemcitabine, and Nivolumab |
2 |
2 |
|
| Cisplatin, Gemcitabine, and Pembrolizumab |
1 |
1 |
|
| Cisplatin, Ipilimumab, Nivolumab, and Pemetrexed |
1 |
4 |
|
| Cisplatin, Nivolumab, and Pemetrexed |
2 |
2 |
|
| Cisplatin and Osimertinib |
2 |
2 |
|
| Cisplatin, Osimertinib, and Pemetrexed |
2 |
2 |
|
| Cisplatin, Paclitaxel, and Pembrolizumab |
2 |
2 |
|
| Cisplatin, Paclitaxel, and Tislelizumab |
3 |
3 |
|
| Cisplatin, Pembrolizumab, and Pemetrexed |
1 |
2 |
|
| Cisplatin, Pemetrexed, and Tislelizumab |
1 |
1 |
|
| Cobimetinib and Vemurafenib |
2 |
4 |
|
| Corticosteroid, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, and Vincristine |
3 |
3 |
|
| Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, and Trastuzumab |
1 |
4 |
|
| Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, and Trastuzumab |
1 |
2 |
|
| Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, and Trastuzumab |
1 |
5 |
|
| Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, and Trastuzumab |
1 |
4 |
|
| Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, and Trastuzumab |
1 |
4 |
|
| Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, and Trastuzumab |
1 |
6 |
|
| Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, and Vincristine |
1 |
2 |
|
| Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, and Vincristine |
4 |
5 |
|
| Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, and Trastuzumab |
1 |
3 |
|
| Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, and Trastuzumab |
1 |
4 |
|
| Cyclophosphamide, Fludarabine, Mitoxantrone, and Rituximab |
1 |
1 |
|
| Cyclophosphamide, Fludarabine, and Rituximab |
1 |
1 |
|
| Cyclophosphamide, Prednisolone, Rituximab, and Vincristine |
1 |
1 |
|
| Cytarabine, Daunorubicin, and Gemtuzumab ozogamicin |
1 |
1 |
|
| Cytarabine, Daunorubicin, and Midostaurin |
10 |
11 |
|
| Cytarabine, Daunorubicin, and Quizartinib |
1 |
2 |
|
| Cytarabine, Dexamethasone, Methotrexate, Ponatinib, Prednisone, and Vincristine |
1 |
2 |
|
| Cytarabine, Idarubicin, and Quizartinib |
1 |
2 |
|
| Dabrafenib and Trametinib |
9 |
31 |
|
| Docetaxel, Pertuzumab, and Trastuzumab |
1 |
6 |
|
| Docetaxel and Trastuzumab |
2 |
6 |
|
| Doxorubicin, Paclitaxel, and Trastuzumab |
2 |
2 |
|
| Durvalumab and Olaparib |
1 |
1 |
|
| Enzalutamide and Talazoparib |
24 |
24 |
|
| Eribulin and Margetuximab |
1 |
1 |
|
| Erlotinib and Ramucirumab |
3 |
3 |
|
| Everolimus and Exemestane |
3 |
6 |
|
| Fluorouracil, Irinotecan, and Panitumumab |
1 |
2 |
|
| Fluorouracil, Nivolumab, and Oxaliplatin |
3 |
3 |
|
| Fluorouracil, Oxaliplatin, and Panitumumab |
2 |
2 |
|
| Fluorouracil, Oxaliplatin, and Tislelizumab |
3 |
3 |
|
| Fluorouracil, Oxaliplatin, and Zolbetuximab |
1 |
2 |
|
| Fulvestrant, Inavolisib, and Palbociclib |
3 |
6 |
|
| Fulvestrant and Palbociclib |
3 |
12 |
|
| Fulvestrant and Ribociclib |
3 |
9 |
|
| Gemcitabine and Margetuximab |
1 |
1 |
|
| Goserelin, Letrozole, and Ribociclib |
3 |
6 |
|
| Idelalisib and Rituximab |
3 |
3 |
|
| Ipilimumab and Nivolumab |
5 |
16 |
|
| Lapatinib and Letrozole |
4 |
5 |
|
| Lapatinib and Trastuzumab |
2 |
2 |
|
| Lenvatinib and Pembrolizumab |
1 |
1 |
|
| Letrozole and Palbociclib |
3 |
6 |
|
| Letrozole and Ribociclib |
3 |
6 |
|
| Margetuximab and Vinorelbine |
1 |
1 |
|
| Nab-paclitaxel and Pembrolizumab |
1 |
1 |
|
| Nivolumab and Relatlimab |
1 |
1 |
|
| Oxaliplatin, Paclitaxel, and Tislelizumab |
3 |
3 |
|
| Paclitaxel and Pembrolizumab |
4 |
8 |
|
| Paclitaxel and Trastuzumab |
2 |
4 |
|
| Pertuzumab and Trastuzumab deruxtecan |
1 |
1 |
|
| Trastuzumab and Tucatinib |
1 |
1 |
|